Neurobehavioral assessment of BMEDA by modified Irwin test in Sprague-Dawley rats.

Autor: Chen LC; Department of Isotope Application Research, National Atomic Research Institute, 1000 Wenhua Road, Jiaan Village, Longtan District, Taoyuan, 325, Taiwan, ROC., Lee TW; Department of Isotope Application Research, National Atomic Research Institute, 1000 Wenhua Road, Jiaan Village, Longtan District, Taoyuan, 325, Taiwan, ROC., Chang CH; Department of Isotope Application Research, National Atomic Research Institute, 1000 Wenhua Road, Jiaan Village, Longtan District, Taoyuan, 325, Taiwan, ROC. Electronic address: chchang@nari.org.tw.
Jazyk: angličtina
Zdroj: Regulatory toxicology and pharmacology : RTP [Regul Toxicol Pharmacol] 2024 Nov; Vol. 153, pp. 105703. Date of Electronic Publication: 2024 Sep 17.
DOI: 10.1016/j.yrtph.2024.105703
Abstrakt: The neurobehavioral assessment of N,N-bis(2-mercapatoethly)-N',N'-diethylenediamine (BMEDA), which can form a chelate with rhenium-188 ( 188 Re) to produce the 188 Re-BMEDA-liposome, was evaluated. The purpose of this study was to evaluate the potential neurobehavioral changes by using the functional observational battery observation procedures when intravenous injection of BMEDA to Sprague-Dawley rats. Rats were administered BMEDA at dose levels of 1, 2, and 5 mg/kg. No mortalities were observed. There are some observations related to BMEDA treatment found in the 5 mg/kg dose group at 10 min post-dose. Tremor was observed in one male rat and seven female rats. The increased respiration, vocalization, not easy to handle and/or loss of tone in the limb were observed in both males and females, and increased body temperature was observed in male animals. Based on the results, a single intravenous dose of BMEDA administered to rats resulted in increased respiration, vocalization, not easy to handle and/or loss of tone in the limb increasing at the dose level of 5 mg/kg. No neurobehavioral effects were noted after BMEDA administration up to the dose level of 2 mg/kg. The information of this study will provides a point of reference to design appropriately therapeutic studies for future human use.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: